Trial reportJAMA2025
Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial.
Trial report in JAMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transanal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer (TaLaR): a Multicentre Randomised Clinical Trial
A Prospective, Randomized, Parallel-Controlled, Superiority Clinical Study Comparing Transanal Total Mesorectal Excision (taTME) and Robot-Assisted Total Mesorectal Excision (RTME) in the Treatment of Low Rectal Cancer
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of preoperative MRI-based pelvimetry in predicting surgical difficulty in rectal cancer: Implications for personalised surgical planning.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Pooled it
- Methodological challenges in surgical randomized trials: systematic review of rectal cancer studies.BJS open · 2026Pooled it
- Multi-database bibliometric analysis and cross-database comparison of NOSES research in colorectal cancer: integrated evidence from WoSCC and PubMed.Frontiers in oncology · 2026Pooled it
- Transanal versus transabdominal total mesorectal excision for rectal cancer in minimally invasive surgery: meta-analysis.BJS open · 2025Pooled it
- Comparison of delayed versus immediate coloanal anastomosis in patients with low rectal cancer: a recent meta-analysis.Frontiers in oncology · 2025Pooled it
- Trial
- Outcomes of transanal vs laparoscopic total mesorectal excision for mid and low rectal cancer under routine clinical practice conditions.Surgical endoscopy · 2026Article
- Repositioning transanal total mesorectal excision in the robotic era.Journal of robotic surgery · 2026Review
- Long-term oncologic outcomes after transanal total mesorectal excision: a single-center cohort with a minimum of 5-year follow-up.Surgical endoscopy · 2026Article
- Essential Updates 2024-2026: Advances in Colorectal Cancer Surgery.Annals of gastroenterological surgery · 2026Review
- Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation.JCO oncology practice · 2026Article
- Development and validation of an interpretable machine learning model for predicting postoperative complications after transanal total mesorectal excision: a multicenter study.Techniques in coloproctology · 2026Article
- Short- and mid-term outcomes of transanal/transperineal minimally invasive surgery for locally recurrent rectal cancer.Techniques in coloproctology · 2026Observational
- Efficacy comparison of preoperative versus postoperative radiotherapy for rectal cancer: an analysis based on the SEER database.Discover oncology · 2026Article
- Magnetic Resonance Imaging Features as Predictors of Response and Prognosis Following Neoadjuvant Therapy in Rectal Cancer: A Retrospective Cohort Study.Clinical Medicine Insights. Oncology · 2026Article
- Deep learning-assisted near-real-time identification of the inferior mesenteric artery and vein during laparoscopic rectal resection: a single-center proof-of-concept study.Frontiers in medicine · 2026Article
- Comprehensive profiling of alternative splicing and immune landscapes in rectal cancer: implications for mRNA vaccine design and immune subtype stratification.Frontiers in oncology · 2026Article
- Construction and external validation of a predictive model for permanent stoma after sphincter-preserving surgery for rectal cancer.BMC surgery · 2025Article
- Current surgical treatment strategies and ongoing issues for locally recurrent rectal cancer.Japanese journal of clinical oncology · 2025Review
- Comparison of short- and long-term outcomes among laparoscopic, robotic-assisted, and transanal total mesorectal excision procedures in patients with rectal cancer: a propensity score-matching analysis.Techniques in coloproctology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Previous studies have demonstrated the advantages of short-term histopathological outcomes and complications associated with transanal total mesorectal excision (TME) compared with laparoscopic TME. However, the long-term oncological outcomes of transanal TME remain ambiguous. This study aims to compare 3-year disease-free survival of transanal TME with laparoscopic TME. Objective: To evaluate 3-year disease-free survival between transanal TME and laparoscopic TME in patients with rectal cancer. Design, Setting, and Participants: This randomized, open-label, noninferiority, phase 3 clinical trial was performed in 16 different centers in China. Between April 2016 and June 2021, a total of 1115 patients with clinical stage I to III mid-low rectal cancer were enrolled. The last date of participant follow-up was in June 2024. Interventions: Participants were randomly assigned in a 1:1 ratio before their surgical procedure to undergo either transanal TME (n = 558) or laparoscopic TME (n = 557). Main Outcomes and Measures: The primary end point was 3-year disease-free survival, with a noninferiority margin of -10% for the comparison between transanal TME and laparoscopic TME. Secondary outcomes included 3-year overall survival and 3-year local recurrence. Results: In the primary analysis set, the median patient age was 60 years. A total of 692 male and 397 female patients were included in the analysis. Three-year disease-free survival was 82.1% (97.5% CI, 78.4%-85.8%) for the transanal TME group and 79.4% (97.5% CI, 75.6%-83.4%) for the laparoscopic TME group, with a difference of 2.7% (97.5% CI, -3.0% to 8.1%). The lower tail of a 2-tailed 97.5% CI for the group difference in 3-year disease-free survival was above the noninferiority margin of -10 percentage points. Furthermore, the 3-year local recurrence was 3.6% (95% CI, 2.0%-5.1%) for transanal TME and 4.4% (95% CI, 2.6%-6.1%) for laparoscopic TME. Three-year overall survival was 92.6% (95% CI, 90.4%-94.8%) for transanal TME and 90.7% (95% CI, 88.3%-93.2%) for laparoscopic TME. Conclusions and Relevance: In patients with mid-low rectal cancer, 3-year disease-free survival for transanal TME was noninferior to that of laparoscopic TME. Trial Registration: ClinicalTrials.gov Identifier: NCT02966483.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.